Novo Nordisk Halts Two More Heart Failure Trials of Ziltivekimab After a Data Committee Found Futility

Novo Nordisk stopped the HERMES and ATHENA heart failure trials of ziltivekimab for futility, ending study treatment for enrolled patients.

Have A Referral?